Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2020-08-24 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
创业板向不特定对象发行可转换公司债券募集说明书
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" which translates to a "Prospectus" or "Offering Circular" for a convertible bond issuance by Jafron Biomedical Co., Ltd. It contains detailed information about the bond issuance, credit ratings, risk factors, company profit distribution policies, financial data, and other disclosures relevant to the offering. This type of document is a capital raising disclosure related to financing activities. It is not an annual report, earnings release, or management discussion, but a detailed financing update and offering document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full prospectus, not just an announcement of a report.
2020-08-24 Chinese
国浩律师（深圳）事务所关于公司向不特定对象发行可转换公司债券之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm (国浩律师（深圳）事务所) regarding the issuance of convertible corporate bonds by 健帆生物科技集团股份有限公司. It references various legal and regulatory frameworks such as the Securities Law, Company Law, and specific regulatory rules for securities issuance. The document includes detailed sections on the approval and authorization of the issuance, the issuer's qualifications, compliance with issuance conditions, and the issuer's independence. It also references audit reports and other legal compliance documents. The document is lengthy (15,000 characters) and contains substantive legal analysis and opinions rather than just an announcement or certification. It is not an annual report, earnings release, or management discussion but a legal opinion related to a capital market transaction. Therefore, the document fits best into the category of Capital/Financing Update (CAP), as it provides a comprehensive legal opinion on the company's convertible bond issuance, which is a financing activity.
2020-08-24 Chinese
关于向不特定对象发行可转换公司债券申请获得深圳证券交易所受理的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the acceptance of its application for issuing convertible bonds by the Shenzhen Stock Exchange. It mentions the regulatory review process and the need for further approvals before implementation. The content focuses on a capital raising activity through convertible bonds, which is a financing update. The document is short and does not contain financial statements or detailed financial data, but it is not merely a report publication announcement. Therefore, it fits best under Capital/Financing Update (CAP).
2020-08-24 Chinese
第四届监事会第五次会议决议公告
Regulatory Filings Classification · 90% confidence The document is a resolution announcement from the Supervisory Board of the company regarding the approval of the audit reports for the fiscal years 2017 and 2018. It mentions that the audit reports were prepared by an accounting firm and are published separately on a regulatory website. The document itself does not contain the audit reports or detailed financial data but announces the approval and references where the reports can be found. The document length is short (762 characters), and it serves as an announcement rather than the audit report itself. Therefore, it fits best under the category of Audit Report / Information (AR) since it relates to audit reports, but given the short length and nature as an announcement, it is more appropriate to classify it as Regulatory Filings (RNS) because it does not contain the full audit report but announces its approval and publication elsewhere.
2020-08-18 Chinese
独立董事关于第四届董事会第五次会议相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent director's opinion on the audit reports for the fiscal years 2017 and 2018. It references the audit reports issued by an accounting firm and confirms their fairness and accuracy. The document is short (517 characters) and focuses on the independent opinion regarding audit reports rather than the full audit reports themselves. It does not contain the full audit report or detailed financial data but rather an opinion on those reports. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2018
2020-08-18 Chinese
2017年度、2018年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report for the years 2017 and 2018 of 健帆生物科技集团股份有限公司. It contains detailed audit opinions, basis for audit opinions, key audit matters, management responsibilities, and auditor responsibilities. It also includes comprehensive financial statements such as consolidated and company balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. The presence of detailed audit procedures, audit opinions, and full financial statements indicates this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2018
2020-08-18 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.